🧠 “To build this genome-wide map, we had to create over 1 trillion neurons, roughly the equivalent of 12 human brains. There was no blueprint for this.” To truly study a disease, you have to work with cells that actually resemble it. In Part 1 of our new series breaking down our end-to-end platform, CEO Najat Khan shares the unprecedented engineering required to map biology at an industrial scale. Starting in 2021, we set out to grow human neurons at scale – executing systematic genome-wide perturbations, and capturing high-dimensional imaging. Using specialized proprietary protocols developed in partnership with Roche and Genentech, we kept these iPSC-derived neurons alive, consistent, and biologically representative. We are already seeing the impact of this work, with Genentech having optioned the first neuroscience target from the collaboration into a joint early discovery program. This is the foundation of high-dimensional target discovery. 🚀 Make sure to follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery.

In our newest episode of TechBio Talks, we explore how AI and clinical data are converging to reshape the future of medicine. CEO of Recursion, Najat Khan, PhD talks with Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital. As a physician, medical geneticist, and investor, Morgan brings a unique perspective, having spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery. We unpack: 🚀How AI is reshaping the fundamentals of biotech value creation 💊Why “modality market fit” is crucial for matching treatments to patient tolerance 🔬Closing the loop between the wet lab, dry lab, and the clinic 🧬Recasting medicine as an information science to close the gap between discovery and care Listen and follow on: YouTube: piped.video/LmVszrLN0cg?si=5ZF_… Spotify: open.spotify.com/episode/6BE…

📣 Presenting updated Phase 1b/2 data on REC-4881 for familial adenomatous polyposis (FAP). Lisa Boardman, MD, a gastroenterologist at the @MayoClinic, will give a Presidential Plenary at the The Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (@CGAIGC) Annual Meeting in Denver. On Nov. 2, 2:30pm, Dr. Boardman will present “Updated Safety And Efficacy Data Of REC-4881 Monotherapy In Familial Adenomatous Polyposis: Phase 1b/2 Trial Results Contextualized With Real-World Registry Data.” 👉 Learn more: cgaigcmeeting.org/wp-content…

🎙️Where AI is genuinely changing drug discovery and development — and where it isn't. Recursion CSO Dave Hallett joined Patrick Short, CEO of @SanoGenetics and host of The Genetics Podcast for a conversation on the real gains and remaining hurdles for AI drug discovery and development. Drawing on his nearly 30 year experience, beginning at Merck in the mid-1990s, Dave shared how AI has fundamentally changed what’s possible  – from research capabilities, to molecule design, to clinical trial planning – but noted that it still can’t change the laws of physics. 🔹Highlights include: ▪️How AI has allowed for true multi-parameter optimization Dave said the shift from single-parameter to true multi-parameter optimization is the biggest change he's seen at the bench. A person can hold roughly six or seven variables in their head at once, a computational system can track far more, without recency bias, across active learning loops. The result: "AI has massively compressed the time and the cost that's required to get from an idea to a candidate." Recursion has seen that show up as roughly 80% reductions in compounds made and 50-70% cuts to time-to-candidate on affected programs. ▪️Simulating trials before running them Rather than copying existing clinical trial protocols, Dave shared how Recursion pressure tests inclusion and exclusion criteria through simulation before a study launches — asking which criteria are actually still fit for purpose. Applied to REC-7735, evaluated in the ZINNIA trial, that process expanded the pool of patients the trial could reach by approximately 20%. ▪️Looking forward with pragmatism and optimism Dave was candid about AI’s limitations, too, noting that the industry is "still a long way" from modeling emergent human pathophysiology at the organism scale. He also discussed Recursion's partnership work on the breakthrough neuro map, and offered advice to early-career scientists: build deep domain expertise while remaining "bilingual" across biology, chemistry, and computation. 👉 Check out the full conversation: piped.video/watch?v=BD34s2h6…

🚀 From data factory to better drugs: inside Recursion's AI-native product engine In our new video, we take you behind the scenes of Recursion’s AI-native data factory and product engine – the first, and one of the largest, of its kind. 💠Capturing Cells AI Can Decipher It starts with perturbing cells via CRISPR and other compounds — dozens of methods at nano scale, generating up to 2 million experiments a week. Recursion’s labs are built to randomize experiments so models learn what's real biology versus noise. Cells are imaged and sequenced at scale, yielding thousands of measurements per experiment — high-dimensional data that trains our foundation models and can be mined again and again. 💠Creating Maps of Biology Our foundation models turn every perturbation — imaging, genetic, and patient data — into a unique fingerprint. Mapping these fingerprints lets us compare genetic manipulations, spot ones with similar effects, and generate new hypotheses for what drives or rescues a disease state. 💠De-Risking Discoveries & Designing New Drugs We validate hypotheses at the bench against the same high bar pharma partners hold themselves to. Each target becomes a chemistry problem, solved in Centaur — our integrated design environment running hundreds of ML and physics-based models. Starting from target properties, we generatively design novel molecules, improving with each cycle. A chemist can run a full design cycle in about a day, using tools like Nesso-1 and in-house AI agents to explore novel chemical space and plan design synthesis. Hundreds of models — ADME, potency, simulations — narrow millions of molecules to a short, makeable list. We’ve produced 10+ development candidates, and each held to that same high bar. 💠Synthesizing Compounds Compounds move directly into automated testing. Scientists describe an experiment in plain language and the platform generates the protocol, cutting pharmacology costs roughly in half compared to industry. Every result feeds back into the models, letting us reach a development candidate with about 90% fewer molecules synthesized than industry average — one closed loop, built to make fewer molecules, not more. 💠Carrying Insights Into the Clinic Clinical candidates enter our ClinTech platform. Our AI compares lab response data to real patient tumors to predict who benefits before enrollment even starts. Our Site Finder tool mines hundreds of millions of patient records to find high-quality trial sites in hours, improving enrollment 30–60% and slashing feasibility and startup timelines. Once running, a biometrics engine turns dose-escalation decisions that used to take 7–10 days into 24–48 hours. This is an end-to-end AI-native product engine that has already put multiple programs in the clinic and is changing the way medicines are made. 👉 Watch the full video: piped.video/watch?v=0T8MlHDr…

As AI in biopharma moves from theory to reality, what’s next? Recursion CEO Najat Khan will be a featured speaker at @Endpts AI Day on Oct. 14 in NYC and online, joining Senior Biopharma Correspondent and AI Day host @AndrewE_Dunn for “Endpoints Takes,” modeled after the internet talk show “Subway Takes” where biopharma leaders offer their most compelling takes on the industry. The theme of this year’s event is “AI in biopharma: no longer theoretical.” Join Najat and other leaders across biopharma, academia, frontier labs, and venture capital – including @nc_frey, Head of Drug Discovery and Development research at #Anthropic and Nobel Prize-winning professor David Baker – for engaging conversations about the future of the industry. 👉 Learn more and register: events.endpoints.news/aiday2…

🎉We won! Proud to announce that Recursion has won a @FiercePharma AI Innovation Award for AI Innovation in Drug Discovery. 💠 The award recognizes the impact of the Recursion OS which connects biology, design, and clinical development into a single AI product engine. They note that this engine is more than a collection of point solutions. “Instead of stitching together fragmented public datasets, Recursion generates its own proprietary data at industrial scale and feeds it directly back into the system.” As CEO Najat Khan says: “It enables our scientists to generate and test hypotheses at a scale and resolution that simply wasn’t possible before, uncovering novel biology and designing more precise medicines faster for patients who are waiting. And it has delivered tangible proof points – including multiple drugs advancing in our internal clinical and pre-clinical pipeline, and ongoing milestones for pharma partners.” Those proof points include REC-4881 for FAP (familial adenomatous polyposis). “REC-4881 marks the first potential treatment for the condition and the first clinical validation of the Recursion OS, backed by encouraging Phase 2 data,” they write. “The same platform also uncovered a novel mechanism for treating FAP – MEK 1/2 inhibition – and used real-world data to broaden patient eligibility for the trial.”  We’ll be presenting additional Phase 2 data from the TUPELO trial at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in November. 🚀 We’re thrilled to have won this recognition from Fierce and look forward to continuing to demonstrate proof points from both partnerships and clinical programs. 👉 Read more: fiercepharma.com/ai-and-mach… #FierceAIInnovationAwards

Recursion CEO Najat Khan, PhD is speaking at the World Medical Innovation Forum in Boston on Sept. 23 as part of the panel “Riding the AI Tsunami: How Organizations Are Driving Cultural Change.” The Forum is presented by @MassGenBrigham and @BankofAmerica, and brings together global leaders across healthcare, life sciences, and investment to assess what’s advancing and what it takes to move innovation at speed and scale. 👉 Learn more and register here: 2026.worldmedicalinnovation.…

🎯Working on difficult-to-drug targets can feel like walking a tight rope through chemical space. At Recursion, we’re using AI agents to work alongside our scientists, and help us navigate that tight rope with precise steps. We’re making 97 billion predictions across 5.5 billion compound records traceable to the design runs that made them and the problem the designer was trying to solve. That gives future agents a playbook to follow. With automation and our BioHive-2 supercomputer, we run calculations proactively for each project compound. That ensures that our design agents have a rich context for interpreting experimental data. And agents don’t just give us predictions – but explanations. When a chemist asks how to improve potency, the agents identify an insight from a compound the team had set aside due to solubility issues. Then it explains why. The agent pulls in precomputed physics-based calculations to show that this gain isn't a new interaction. It's a conformational strain. that tells the team exactly how to redesign. Using AI agents in the chemical space, we’re moving faster. And as this drug design lab-in-the-loop cycle continues, we’re building up an immense catalog of design knowledge that agents are helping to unlock.

📣 In a new story in @GENbio, @AlexWestchester spoke with Recursion VP of Neuroscience Chris Winrow about the delivery of the first neuroscience target from our partnership with Genentech, which has now been validated and is advancing in a joint early-discovery program. Neuroscience is one of the toughest areas in drug development. More than 3 billion people live with neurological conditions, yet only 1 in 40 neuroscience drugs that reach the clinic are ever approved. To find new biology, the team built the first whole-genome CRISPR knockout map from over a trillion neurons derived from induced pluripotent stem cells — roughly 12 brains' worth of cells. “The cell context is important. We’re starting with human iPSCs and driving these into a very clearly homogenous population of neurons that we can test—and we do this at scale,” Winrow said. The screen spanned 17,000+ genes and thousands of small molecules, generating 46 million+ cellular images analyzed across hundreds of features (mitochondrial shape, nuclear morphology, and more) using AI foundation models and Recursion's BioHive-2 supercomputer. “You look for what we would call gene-compound interactions, to uncover some of those insights, at the same time as looking at the gene-gene interactions.” He added: “We’re looking at whole genome-wide knockout, not just a handful of areas or pathways of interest. That’s really a big game changer, in that we have this broad view.” he added. This and other maps developed in the partnership (including a whole-genome microglia map) will continue to be mined for additional programs. 👉 Read the full story: genengnews.com/topics/artifi…

🚀 How we unlocked the first neuroscience target for the Recursion and Genentech collaboration. The collaboration began with a mission to unlock new targets in one of medicine's most challenging therapeutic areas: neuroscience. Today, that work has reached an important milestone, with the first previously unexplored neuroscience target advancing into a joint early discovery program. In a new story from @fabiennekatrin in @business – and our latest blog – we share how the team developed new manufacturing processes to produce more than 1 trillion hiPSC-derived neuronal cells, systematically perturbed 17,000+ genes, captured 30 million+ cellular images, and built a foundation model to create an AI-enabled Map of Biology capable of surfacing unexplored biology in neuroscience. 🔹 What made this approach unique and what were the outcomes? ▪️We built disease-relevant human models with high-dimensional data, generating disease-relevant biology at unprecedented scale ▪️We explored the human genome at scale, identifying unexplored biology from our maps, reviewed and prioritized by scientists ▪️We navigated from known to unknown biology, developing a ranked list of potentially novel, biologically connected targets ▪️We validated experiments with Genentech, resulting in their decision to advance a target into an early discovery program 🎁 Read the Bloomberg story with this gift link: bloomberg.com/news/articles/… 👉 Check out the blog: recursion.com/news/unlocking…

Today, Recursion reports its second quarter financial results and business updates, showing demonstrated progress across partnerships, clinical programs, and financial goals. 🚀 Highlights include: ▪️Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery ▪️ REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026 ▪️ REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα ▪️Reduced 2026 cash operating expense guidance to <$375 million (from <$390 million) "Recursion has reached a pivotal point where our AI-native engine is translating unique data into potential first-in-class therapeutic opportunities," said Recursion CEO Najat Khan, PhD. "The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled." 💠 Recursion will host an Earnings Call today, August 5, 2026, at 8:00 am ET / 6:00 am MT / 1:00 pm BST. Join on: ▪️X: nitter.net/i/broadcasts/1XxyggqLb…: ▪️YouTube: piped.video/live/kJMGIjhRmpA… ▪️LinkedIn: lnkd.in/p/e9nMeUQP Analysts, investors, and the public have the opportunity to ask questions of the Company by submitting questions here: forms.gle/mWY8bBLMpGG9z3QJ7

Recursion will host its second quarter financial results and business updates in an Earnings Call on August 5, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. Join the call on: ▪️LinkedIn: linkedin.com/company/recursi… ▪️YouTube: piped.video/@RecursionPharma ▪️X: nitter.net/RecursionPharma Analysts, investors, and the public have the opportunity to ask questions by submitting questions here: forms.gle/tcYtfHRL8KagYZQw9 👉More: ir.recursion.com/news-releas…

We’re improving clinical trials with AI before the first patient enrolls. A new article from Brian Buntz in @RandDWorld highlights the current roadblocks in clinical trials and how Recursion is improving the process with a data- and AI-driven approach. Today, protocols are on the rise, meaning more endpoints, procedures and eligibility rules. “The share of Phase 1 through 4 protocols requiring at least one amendment hit 76%, up from 57% in 2015,” the story notes. Through an expanded partnership with Norstella's @Citeline, Recursion is stress-testing protocols against real-world patient data before committing resources: mapping how each eligibility criterion changes who actually qualifies, catching when a protocol is "so scientifically perfect" it can't be operationalized, and simulating enrollment scenarios in real time. Since Recursion was built as an AI-first company, “you get to try different approaches,” says Sid Jain, SVP of Clinical Development. “What makes it really hard to deploy AI and technology is exactly that 20 or 30 years of legacy technology silos, which we frankly don’t have to deal with. We can design these systems for a very modern architecture and take advantage of the latest and greatest technology.” This ClinTech approach is delivering results in Recursion’s pipeline, including expanded eligibility criteria in our REC-4881 program, and beating historical enrollment projections by 30-60% in most clinical studies by identifying the right sites and countries from day one. We're not just discovering drugs differently. We're running trials differently — and it's translating into faster, smarter execution across our clinical pipeline. 👉 Read more: rdworldonline.com/recursion-…

@HoifungPoon, PhD, formerly General Manager of @MSFTResearch, has joined Recursion as the company’s first Chief AI Officer. He spent more than 15 years at Microsoft and led pioneering work in biomedical AI, multimodal foundation models, and causal machine learning. His contributions – including PubMedBERT, GigaPath, and GigaTIME – have helped shape the field and are advancing biomedical research around the world. As Recursion CEO Najat Khan said: “His decision to join Recursion reflects our shared belief that we're entering a new era – one where the deepest advances in AI will come not from models alone, but from tightly integrating AI with experiments, data generation, and drug discovery to create medicines.” More: lnkd.in/p/g-AkZwx3

📣 Presenting a new method for recognizing which tumors are most likely to benefit from dsRNA therapies. At @AACR Drug Discovery and Development (AACR D3), July 21-24 in Boston, Recursion will present the poster “Identifying actionable dsRNA biomarkers from sense-antisense transcript pairs,” a new computational approach for identifying which patients are more likely to benefit from dsRNA-inducing therapies or immunotherapy combinations. Some new cancer therapies work by increasing double-stranded RNA (dsRNA) inside tumor cells, a molecular pattern the body usually associates with viral infection. When dsRNA builds up, it can switch on antiviral immune pathways, drive cancer cell death, and strengthen anti-tumor immunity. The problem is measurement: dsRNA is hard to quantify with conventional approaches, where the signal is often noisy and the dynamic range is low, so drug-driven changes can be easy to miss. Recursion’s poster describes a computational pipeline that recovers this dsRNA signal from standard RNA sequencing (RNA-seq) data. The pipeline looks for sense-antisense transcript pairs, where two RNAs transcribed from overlapping regions on opposite DNA strands bind to each other to form dsRNA. To confirm which pairs genuinely form duplexes, researchers combined this with an experiment that sequences only dsRNA, isolating the pairs that truly bind together. With this filtering, targeting enzymes that regulate dsRNA produces rapid, dose-dependent increases in dsRNA that look flat in standard analyses. Across cell lines and models, there is repeated evidence of a conserved set of dsRNA-forming pairs. Scoring these pairs in patient tumor datasets highlights cohorts with elevated baseline dsRNA that may be more likely to benefit from dsRNA-inducing therapies or immunotherapy combinations. ▪️Abstract: Identifying actionable dsRNA biomarkers from sense-antisense transcript pairs ▪️Session: Poster Session A ▪️Session Date and Time: Wednesday, July 22, 6:15-8:45pm ET 👉 Learn more: aacr.org/meeting/aacr-d3-202…

🚀 A better, faster co-folding-based binding affinity model. Predicting how tightly a drug candidate binds to its target is critical in drug discovery. It also requires massive computational resources. State-of-the-art models can take 20 seconds to a minute per prediction, impractical for the demands of large scale early-stage programs . 💠 Today, Recursion’s @Valence_ai is releasing Nesso-1: the fastest open-source co-folding-based binding affinity model available. At 1 second per prediction, it’s roughly 20x faster than our previous collaboration on Boltz-2 while matching or surpassing its accuracy across public and internal benchmarks. By leveraging @NVIDIAHealth cuEquivariance, we’ve been able to further accelerate both training and inference by an additional 2-3x. We look forward to continuing to improve Nesso-1 in collaboration with @NVIDIA. Weights and code are fully open-sourced. The core architectural ideas behind Nesso-1 build on the insight that coarse-grained co-folding representations can match full-atom models for affinity prediction at a fraction of the cost. Nesso-1 is the first open implementation of this approach with no proprietary dependencies, trained entirely on public data, built to be reproducible and extensible. We’re already using Nesso-1 internally in active drug discovery programs. Fast, reliable affinity prediction at scale is foundational to the kind of autonomous design loops that define our vision for Autonomous Precision Design and Nesso-1 is a meaningful step toward that. 👉 Report: valencelabs.com/wp-content/u… 👉 Github: github.com/recursionpharma/n… 👉 HF: huggingface.co/recursionphar…

Recursion’s AI research arm, @valence_ai, had a great time at @icmlconf in Seoul last week. 💠We shared our latest model updates, including AquaGen, a new generative model that produces physically realistic molecular configurations, including water, 4–10x faster than traditional molecular dynamics. 💠We checked out the terrific keynote on Lab-in-a-Loop for Drug R&D from Aviv Regev on how AI drug discovery works: collecting large-scale data at high-resolution from human biology and combining these large datasets with AI to yield testable predictions of missing information and iteratively improve models. 💠And we gathered over 100 people working in and around AI drug discovery for a TechBio Social. See you next year!

On July 21, 12pm EST, Recursion CEO Najat Khan will join @BiotechTV’s inaugural U.S. Science Summit in Kendall Square for a fireside chat, “Who Will Shape the Future of Medicine?” Together with moderator Katherine Andersen, Head of Life Science & Healthcare at @HSBC and Joanne Kamens, CEO of @WomenInBio, she will explore: why biotech matters; how AI is transforming drug discovery while keeping people at the center; and what skills the next generation of scientific and business leaders need. 👉 biotechtv.com/us-science-sum…

💡 New computational tools are lowering the barrier to entry for drug discovery – but data is still the differentiator. A new story from David Wild in In Vivo looks at how computational tools are making drug discovery accessible to a much broader population – and even high school students are designing promising new molecules. Interviewed for the piece, Recursion CTO @BMabey noted that powerful structure-prediction models are now widely accessible. “Some of these models would have been groundbreaking ten years ago. Now anyone can download them.” At the same time, he underscores that the hardest problems still depend on proprietary, large-scale datasets — especially in phenotypic screening, where Recursion’s high-content imaging and foundation models like OpenPhenom require massive, purpose-built data to uncover novel biology. Ben draws a sharp distinction between open models and closed data: “You’re seeing less of the data being made available, because that’s where a lot of the value is. Companies are far more protective of the data, because that’s where the therapeutic insights are going to be found.” At Recursion, we’re excited about how democratized tools will bring more ideas and talent into drug discovery — and we remain focused on generating the rich experimental datasets needed to turn those ideas into transformational medicines. 👉 Read the article: insights.citeline.com/in-viv… @Citeline

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from @CMC_Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation: piped.video/watch?v=XF__xwKq…

📈 Toward safer, faster, first-in-human studies. Recursion’s clinical development and biometrics teams are rethinking how early-phase trials run in practice — starting with how quickly dose-escalation decisions get made. A case study from @posit_pbc highlights Recursion’s ClinTech advances – including turning around dose-escalation reviews in just 24-48 hours compared to previous rates of 7-10 business days — a 7x faster data-to-decision cycle. Instead of PDF snapshots, investigators and medical monitors now have governed self-service access to live trial data: cohort-level overviews, patient-level safety signals, and targeted visualizations designed around the questions they most need to answer. This is bringing new efficiency to how we run clinical trials and laying the foundation for the next phase: AI-enabled clinical workflows that can support the FDA’s vision for real-time clinical trials. 👉 Read more: posit.co/about/customer-stor…

🤖 Automated labs will be a driving force in the AI drug discovery era. A new story from @patrickcsisson for @sciam looks at how automated labs are adding new speed and efficiency to drug discovery and development. Recursion, he notes, is bringing “industrial scale” to lab automation, running up to 2.2 million experiments a week and processing “more than 50 petabytes of proprietary data through BioHive-2, its in-house supercomputer” using that data “to map biological processes and search for unexpected drug targets.” The story cites Recursion VP of Neuroscience, Christopher Winrow, who shares how Recursion has used automated labs to develop both an in-house clinical-stage pipeline and “large-scale cellular maps, using models of neurons and microglia” with pharma partners. The story notes: “The rest of the pharmaceutical industry is moving in the same direction” in its effort to bring down costs and improve success rates of new therapeutics. 👉 Read more: scientificamerican.com/artic…

For FAP Awareness Week, we want to highlight one of the strongest advocates in the space. Living with the rare disease familial adenomatous polyposis (FAP) means a lifetime of uncertainty, surgeries, and complications. Jenny Jones, founder of Life's a Polyp Foundation, along with her dad, Timothy Jones, shared what that journey has looked like for their family – where not only Jenny, but her mother and grandfather, struggled with the disease which results in hundreds to thousands of polyps developing in the GI tract that have 100% likelihood of turning cancerous if not removed. Once she was diagnosed at age 8, Jenny says, FAP became a part of her daily life. By age 10, she’d had multiple surgeries, including the removal of her colon. Her dad called it a miracle that she survived. The major surgeries continued throughout her life – and have led to numerous challenges, including nutrient deficiencies, dehydration, limitations in what she can eat, painful bowel movements, and medical PTSD. “It’s something that’s always on the mind,” she says. Jenny has now dedicated her life to serving as a resource and building a trusted network for the FAP community via her foundation, and supports research into new treatment options for FAP patients who currently have no non-surgical options available. Recursion is working toward solutions for patients with FAP. 👉 Learn more at: recursion.com/

Recursion is advancing the first potential drug for rare disease FAP, discovered with AI. For FAP Awareness Week, we’re resharing our video featuring CEO and President Najat Khan, announcing the first clinical validation of Recursion’s AI-enabled drug discovery platform – positive Phase 1b/2 data for AI-identified drug REC-4881 in Familial Adenomatous Polyposis (FAP). This progressive rare disease – which often begins in the teens and results in hundreds or thousands of polyps developing in the GI tract which have a 100% likelihood of becoming cancerous if not removed, requires a lifetime of invasive surveillance and life-altering surgeries. There are currently no FDA-approved treatments. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. This program is the first clinical validation of the Recursion OS, and demonstrates our ability to translate unbiased phenotypic insights into potentially differentiated treatments for diseases with high unmet need. We’re working hard to advance new solutions for FAP patients, this week and every week.

🎉 We’re on the Shatter List! Recursion has been named to the 2026 Women Tech Council’s Shatter List. This is our 9th year making the list, which recognizes workplaces where talented people want to grow, lead, and build meaningful careers. 💠 This year, Recursion has earned recognition in the Community Choice category, which highlights: 🙌 Companies people most want to work for right now 🚀 Strong cultures that attract top talent and enable career growth 🌟 Visionary leadership in a rapidly evolving economy 👉 Learn more: womentechcouncil.com/shatter…

“In its quest to transform how medicines are made, engineering, AI-pattern recognition, and cloud computing have proven as necessary as biochemical expertise.” A recent Case Study from @googlecloud highlights how Recursion is accelerating new treatments using the Recursion OS platform which “supports bursts of computational power that weigh in at trillions of calculations per second.” Combining a data-driven understanding of biology and chemistry with the latest in machine learning tools, the study notes that Recursion is advancing a pipeline of clinical stage drugs, including REC-4881, a potential first-in-disease treatment for the rare disease Familial Adenomatous Polyposis (FAP) that is one of the most advanced AI drugs in development today. “Recursion has reached an inflection point — from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value,” notes CEO and President Najat Khan. In addition to five drugs advancing through clinical trials in Recursion’s internal pipeline and with partners like @sanofi and @Roche and @genentech, the study notes that Recursion has developed a suite of state-of-the-art machine learning foundation models, and maps of biology both internally and with partners (including the world's first whole-genome Neuromap and Microglia Map) that are uncovering unknown biology in difficult areas like neurological diseases. Leveraging a hybrid computing approach – training models on Recursion’s supercomputer, BioHive-2, and running inference on Cloud GPUs and TPUs – has allowed Recursion to continue to scale efficiently. "The potential of using Cloud TPU pods to accelerate our research while keeping operational costs and complexity low is a big draw," says CTO @bmabey. 👉 Read more:  cloud.google.com/customers/r…

Donovan Chin is joining Recursion as Senior Vice President of Drug Design, effective June 22. His career spans small molecules, RNA-targeted therapeutics, novel peptide modalities, and AI-enabled discovery platforms. At Parabilis, Donovan led the computational drug discovery strategy behind Helicons, a novel class of constrained alpha-helical peptides that helped advance a first-in-class β-catenin inhibitor program to FDA Fast Track designation. At Arrakis Therapeutics, he pioneered computational approaches for RNA-targeted drug discovery, helping unlock small-molecule engagement of previously inaccessible RNA structures. Earlier at Novartis, he helped pioneer the application of computational approaches to drug discovery, building capabilities that supported a diverse portfolio across oncology, cardiovascular and metabolic disease, infectious disease, and chemical biology. Throughout his career, he has built high-performing multidisciplinary teams and advanced programs at the intersection of computation, chemistry, and biology – the same intersection where we believe the next generation of medicines will be discovered. Welcome to Recursion, Donovan!

One of the most important applications of AI is in improving clinical trials which encompass up to 70% of R&D costs and where most drugs in development fail. On June 17, 4:20pm at @HLTHEVENT Europe in Amsterdam, Recursion CFO Ben Taylor will present on the panel “Trials & tribulations: Exploring the next frontier in evidence generation,” looking at the rise of new clinical models that are shifting the traditional framework – including in silico models, digital twins, synthetic controls, adaptive frameworks, and hybrid or decentralized trials. He’ll be joined by Mati Gill, CEO of @AionLabs; Peter Donnelly, Co-Founder & CEO of Genomics; and Yajing Zhu, Director, Computational RWE at @novonordisk. Moderated by Adama Ibrahim, President, Digital Transformation at Crest Meridian, the panel will explore how clinical trials have evolved, expected breakthroughs on the horizon, and how pharma can prepare for a world where evidence generation is faster, more diverse, and increasingly augmented by technology. 👉 Learn more: hlth.com/events/europe/agend…

💡“Just like we simulate molecules and we simulate biology, what if we could simulate our trials before we run them?” In this clip from CEO and President Najat Khan's conversation with Selina Koch for the @BioCentury Show, she talks about where AI is making an impact on clinical trials. 💠Recursion’s approach is focused in three areas, Najat says. 1. Improving patient stratification - “Can you improve the signal to noise to know which patients would better respond?” 2. Smarter protocol design and simulating the protocol. 3. Improving recruitment and enrollment. “80% of trials don’t recruit on time.” 👉 Watch the full conversation here: piped.video/watch?v=LfGy7FvH…

🚀Clinical momentum, capital efficiency, and high-quality data. Ben Taylor, Recursion CFO and President of Recursion UK, sat down recently with Alec Stranahan at the @BankofAmerica Global Healthcare Conference, highlighting how Recursion’s data- and AI-led approach is building a more predictive, risk-diversified model to get better medicines to patients faster. 🔹 Here are three key takeaways: 1. It’s all about patient impact. As Ben noted, every part of the Recursion OS is designed to increase the probability of clinical success. "At the heart of it, we're a therapeutics company. And so we really focus on making sure that we're advancing the pipeline.” 2. Data quality is essential. As the industry rushes to train foundation models, Ben stressed that simply having massive amounts of data isn't enough. It’s about quality. "If you're just using public data or even if you're just using data that has been generated outside of the ML context, the fidelity of it is pretty low,” he said. “A much smaller data set of highly annotated data actually creates far more predictive models than a massive data set of poorly annotated data." 3. Driving capital efficiency with technology. Recursion is leveraging technology not only to advance new medicines, but to radically improve the unit economics of drug discovery – applying a strict analytical framework to ensure that capital flows directly to value-driving programs. “We should always be getting more impact for less cost,” Ben said. “Right now, most people don't realize this, about two-thirds of our cost is going directly into pipeline programs and our partnerships." With continued pipeline momentum and catalysts across multiple clinical programs over the next 12-18 months, we are demonstrating clear proof points for our data- and AI-led approach. 👉 Catch the full session here: bofa.veracast.com/webcasts/b…

Join us at the AI Compute Summit in Amsterdam! Maureen Makes, VP of Engineering at Recursion, is speaking May 19 on the panel “People, power and performance" at the 2nd annual AI Compute Summit in Amsterdam from @TheEconomist Enterprise. Along with Marina Antoniou, Global Markets Head of Market Abuse Risk Assessment at @NatWestGroup; Rui Oliveira, Director of the Minho Advanced Computing Centre; and Valeriu Codreanu, Manger of Compute Services at SURF, they’ll discuss how AI infrastructure is expanding faster than the talent to run it, and how organizations can reskill teams and develop leadership for a world defined by GPUs, automation and data governance. The panel will be moderated by Matus Samel, Principal of Energy & Sustainability at Economist Enterprise. 👉 Learn more and register: events.economistenterprise.c…

🧬 Bridging the gap in AI drug discovery. @AlisandraDenton, Staff Machine Learning Scientist at Recursion and one of the authors on our recent paper in @NatureBiotech, explains how the AI model TxPert predicts how a cell will respond to perturbations. Predicting a cell’s RNA activity, or transcriptome, is key to bridging the gap between cellular changes and clinical outcomes and advancing the potential for AI drug discovery. As Ali says, “with hundreds of cell types and so much disease variation, the total possibilities are too vast to measure in a lab.” She describes how TxPert allows us to perform a “Virtual Assay,” taking the mathematical signature of a healthy cell called the Basal State and adding the perturbation’s embedding to deliver a highly accurate prediction of what the cell’s transcriptome will look like after treatment. TxPert uses layered graph-based models that integrate phenomics — or how a cell looks — and transcriptomics — which genes are expressed — along with massive public biological knowledge resources. The model can even predict how a perturbation will work in entirely new cell lines it hasn’t seen before as well as accurately forecast the effects of “double perturbations,” consistently identifying "unknown unknowns" that traditional models — and even massive general-purpose AI — often miss. Ali notes that TxPert is currently predicting genetic perturbations, but more flexible models —  including those predicting drug effects — are in the works. 👉 Check out the full paper in Nature Biotech: nature.com/articles/s41587-0…

Recursion Chief Scientific Officer Dave Hallett will give a keynote presentation at Drug Discovery Europe on June 15, 9am in Berlin. In a talk titled “The Automation & AI Landscape In 2026,” Dave will demystify the term “lab-in-a-loop” and detail some of the major advances that have been made in autonomous science and drug discovery. He’ll share how Recursion is operating at the interface between the physical world and the virtual world and how the company has built the infrastructure required to enable agentic orchestration of the AI-driven, iterative, design-make-test-learn approach that refines small molecule therapeutics into highly optimized drugs for challenging targets in diseases with high unmet need. 👉 Learn more and register here: oxfordglobal.com/discovery-d… @OGConferences

“What’s the one question we obsess over at Recursion? ‘How do we harness the full power of AI to consistently and with urgency create better medicines for patients’?” In a recap of Recursion’s recent 1Q earnings, CEO and President Najat Khan talks about the tangible evidence that Recursion’s AI platform is delivering. 🔹 They include: ▪️  REC-1245, a potential first-in-class oncology program where both the biology and molecule were discovered using the Recursion OS. Early clinical data shows a well-tolerated profile with no dose-limiting toxicities and an encouraging PK profile, with more data expected in the second half of this year. ▪️  REC-4881, a potential first-in-disease program for the rare disease FAP that has already shown strong proof of concept with meaningful and durable impact. We’ve now initiated engagement with the FDA on a potential path to registration, with an update expected in the second half of this year. ▪️  REC-4539, a potentially best-in-class LSD1 inhibitor for small cell lung cancer and AML in which the first patient was recently dosed in the Phase 1 trial. “This is a precision-designed molecule,” Najat says, “built to address class-limiting toxicity” with the potential for “improved safety and CNS penetration.” It’s not about one asset, Najat says, but building a “repeatable, AI-driven product engine that’s starting to deliver across discovery and into the clinic.” 👉 Read Recursion’s full earnings report here: ir.recursion.com/news-releas…

"Bigger isn't always better.” — Dave Hallett, CSO of Recursion At the recent @SynBioBeta event, Dave joined fellow industry leaders from @Xaira_Thera, @GSK, @NOETIK_ai and @nvidia to discuss one of the most pressing issues in AI drug discovery: "Solving the Scale Mismatch Between Cells and Patients in Virtual Biology." How do we better translate cellular insights to patient outcomes using AI – and change drug discovery’s 90% failure rate? 💡 Key insights include: ▪️ Context Is Everything: “It is important to generate high quality, high value, large perturbational datasets, but you also need to do that in context,” Dave said. That’s why Recursion is increasingly moving toward multimodal data generated in highly specific contexts. ▪️ Engineering Needs to Match Human Reality: As Dave pointed out, the closer a model gets to a human, the harder it is to scale perturbational data. Recursion is bridging this gap by moving toward complex, engineered systems like iPSC-derived neurons and engineered cancer cell lines, and then, “Perturbing those at genome scale. And then integrating in over a dozen cellular systems,” merging phenotypic, transcriptomic, and proteomic data. ▪️ Quality Over Scale: Dave noted that while massive public datasets like single-cell transcriptomics exist, the variation in how that data was collected across different labs often results in models that memorize technical noise rather than biological truth. To build accurate foundation models—like Recursion’s recently announced state-of-the-art transcriptomic foundation model known as TxFM—he said we need high-quality, standardized, multimodal data and model architecture that accurately reflect unordered, interconnected biological states. Thank you to @StacieCT for moderating an excellent discussion, and to Marc Tessier-Lavigne, Kim Branson, and @Ronalfa for sharing their perspectives on the future of virtual biology.

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with @sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to @Roche and @genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: piped.video/live/mnLb-AaPgHo ▪️ LinkedIn: linkedin.com/events/74552259… 👉 Analysts, investors, and the public can submit questions here: forms.gle/TQ4vgUTLKsFmikcu6. 👉 Read the full report: ir.recursion.com/news-releas…

A new story in @biospace from Annalee Armstrong captures the inspiring presentation from FAP advocate Jenny Jones, who recently visited Recursion with her father, Timothy. They “offered a powerful reminder of why they were all there,” the story notes. Familial adenomatous polyposis is a rare disease that requires a lifetime of surgeries and has affected the Jones family for generations. It often begins in childhood, and results in hundreds to thousands of polyps developing in the colon and rectum that will turn cancerous if not removed. Jenny’s own FAP journey began with chronic abdominal pain at age 7. “She remembers a doctor telling her she was ‘whiny’ — despite the verified family history of FAP,” the story notes (both her mother and grandfather died from FAP complications). Jenny was diagnosed at age 8 and had her colon removed at 9. She would have eight surgeries throughout her life, including her gallbladder removed at age 36, when doctors found a polyp. The story highlights Jenny’s resilience in the face of not only physical but mental battles brought on by her disease and its complications. She has devoted her life to improving education and outcomes for other people living with FAP through her nonprofit, Life’s a Polyp Foundation, and she called on the assembled Recursionauts to continue to work toward non-surgical treatment options. 👉 Read the story in Biospace: biospace.com/drug-developmen… 👉 For full information about our program, see the press release here: ir.recursion.com/news-releas…

🧬 Closing the translation gap between cells and patients. 😷 @NatureBiotech just published a new paper from Recursion on TxPert – a deep learning framework that accurately simulates the transcriptomic shift in unseen biological contexts. TxPert represents an important step in our ongoing work to accurately model transcriptomics and bridge the gap between in vitro discovery and clinical reality – which is critical for improving and scaling AI drug discovery. 🔹 TxPert address this translational gap through: ▪️ Graph Neural Networks (GNNs): Rather than treating genes as isolated lines of code, TxPert uses an advanced Exphormer-MG architecture to map genetic perturbations across multiple, massive knowledge graphs, forcing the model to understand both the physical (phenomic) and molecular (transcriptomic) realities of a cell simultaneously. ▪️ Simulating the "latent shift": By mathematically applying a "perturbation embedding" to a cell's baseline state, TxPert can accurately predict the entire post-perturbation transcriptomic profile—without anyone ever having to touch a pipette. ▪️ Predicting unseen biology: TxPert successfully predicts the transcriptomic outcomes of completely unseen single perturbations, complex combinatorial therapies (Double Perturbations), and even how known drugs will act in entirely new, unseen cell lines. TxPert is one of several models at Recursion to model transcriptomics and close the translation gap between cell responses and patients in the clinic. 🎉 Congrats to the team! Frederik Wenkel, Wilson Tu, Cassandra Masschelein, Hamed Shirzad, Liam Hodgson, Ihab Bendidi, Cian Eastwood, Shawn Whitfield, Craig T. Russell, Yassir El Mesbahi, Marta Fay, @bertonearnshaw, @ENoutahi, and @AlisandraDenton. 👉 Read the full publication in Nature Biotech here: nature.com/articles/s41587-0…

We had a fantastic time with @valence_ai at @iclr_conf in Rio sharing our latest machine learning breakthroughs, including presentations on TxFM, our state-of-the-art transcriptomics model that outperforms models up to 100x larger in terms of data size, and MarS-FM, our new class of generative models for molecular dynamics simulations. And there were lots of great community conversations happening at the rooftop TechBio Social, co-hosted with ICLR’s Learning Meaningful Representations of Life (LMRL) Workshop. Coming soon: we’re looking forward to sharing more of our ML breakthroughs at @icmlconf! 👉 TxFM paper here: openreview.net/pdf?id=NqZqCl… 👉 MarS-FM paper here: arxiv.org/html/2509.24779v3

Join our first quarter Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. Tune in here on X or on our LinkedIn or YouTube. 👉 Investors, analysts, and the public may submit questions here: forms.gle/TQ4vgUTLKsFmikcu6. nitter.net/i/broadcasts/1AJEmOVoY…

⏩ Momentum is building across the TechBio ecosystem. Annalee Armstrong’s recent story in @biospace captures the momentum happening across biotech – and across our thriving local Salt Lake City biotech hub. She toured Recursion-supported incubator @AltitudeLab and visited Recursion headquarters. There, she writes: “I sat in on an all-hands meeting where staff got to hear about the true impacts on a family of the incredibly difficult disease called familial adenomatous polyposis. The inherited disorder causes noncancerous polyps to grow in the colon and rectum as early as the teenage years. While patients can live with the disorder, they often face early cancers and immense, life-altering complications.” The experience was a reminder, she wrote, that “after a year of keeping its head down and riding out the bumps, biotech is doing what it’s best at again. Innovating. Making things better.” We couldn’t agree more. 👉 Read the story: biospace.com/drug-developmen…

Last Wednesday at our company All Hands, we welcomed two very special guests from Oklahoma City to share their stories: Jenny Jones and her father, Timothy Jones. Jenny has familial adenomatous polyposis (FAP), a progressive rare disease that involves hundreds to thousands of polyps developing in the colon and rectum that have a nearly 100% likelihood of developing into cancer if not removed. Jenny was first diagnosed when she was 8. After her stomach pains as a child turned out to be precancerous polyps from FAP, she had her colon removed at the age of 9. She would continue to have complications from the disease throughout her life – including having her gallbladder removed at the age of 36. Now, she’s on a mission to provide support for FAP sufferers – to raise awareness, encourage regular surveillance, and to provide encouragement to others who are dealing with FAP, a disease that often strikes very young. She started the Life’s a Polyp Foundation where she shares research, education and events, and even wrote a children’s book – Life’s a Polyp with Zeke and Katie – to help reduce anxiety in young patients. Jenny and her dad talked about how they have navigated this disease as a family. Her grandfather died of FAP-related cancers and her mother, who also had FAP, spent 28 days in the hospital not long after Jenny was born when doctors discovered cancer. Her mother had her colon and rectum removed at age 34 and required a permanent ileostomy, rerouting waste to an external bag. She would later develop polyps in her bile duct and undergo a Whipple procedure – the removal of the gallbladder, part of the bile duct, part of the stomach and other organs. Her mom lived to be 73, Jenny said, a fighter until the end with an unbelievable “zest for life.” “She did not want to go,” Jenny said during the presentation, “which was the heartbreak that I had to tell her, ‘You're going to have to go, Mom’.” A consistent message from their talk was the critical role of awareness and monitoring – and community. “Community is life changing,” Jenny said, “especially with a rare disease. So we want to connect people to resources, to support, and then research.” She said the foundation is dedicated to helping fund new treatment options for FAP patients where surgery is currently the only option. “I want to go from we're delaying it to we're preventing it,” she said. 👉Check out Life’s a Polyp Foundation and learn more about FAP and supporting research initiatives: lifesapolyp.org/

We had fantastic turnout at our panel and poster session at @AACR. AI is no longer a side discussion at the conference – it’s integrated into every aspect of cancer research, discovery and care. At Recursion, we’re finding new ways to connect our proprietary datasets with real-world patient data to improve causal insights and ensure that we are advancing the cancer drugs most likely to succeed in trials. Teeru Bihani, VP of Translational Strategy at Recursion, spoke about how we’re applying AI to better align preclinical findings with patient outcomes and ultimately close the translational gap in oncology R&D. And we presented a poster on one of those strategies – CellNeighbor – a transcriptional atlas that brings together cell line models and real-world patient cohorts into one embedding space and helps to ensure that our preclinical decisions are rooted in actual patient biology. 👉 Check out CellNeighbor here: researchgate.net/publication…

☀️See you in Rio! Recursion and our AI research engine, @valence_ai, will be at @ICLR April 23-27 in Rio to share some of our latest breakthroughs in generative modeling for AI drug discovery. 🔹 Check out our poster presentations on: ▪️ TxFM: Effective Biological Representation Learning by Masking Gene Expression. A state-of-the-art transcriptomics foundation model that combines Recursion’s proprietary dataset with a highly customized Masked Autoencoder (MAE) architecture to represent genes as they appear in nature (i.e., unordered). It provides a much more accurate representation of how genes interact as a system, connects experimental results directly to patient biology, and outperforms models up to 100x larger in terms of data size. 👉 Paper here: openreview.net/pdf?id=NqZqCl… 👉 Workshop here: Foundation Models for Science - fm-science.github.io/index.h… ▪️ MarS-FM: Generative Modeling of Molecular Dynamics via Markov State Models. We introduce a new class of generative models – MarS-FM (Markov Space Flow Matching) – which offers a a 100x+ speedup compared to traditional MD simulations, without sacrificing structural accuracy. 👉 Code here: github.com/valence-labs/mars… 👉 Paper here: arxiv.org/html/2509.24779v3 🎉 And join us for a TechBio Social on April 26, 6-9pm, co-hosted with ICLR’s Learning Meaningful Representations of Life (LMRL) Workshop, featuring a rooftop bar, waterfront views and engaging conversations about how we can advance the frontier of AI-powered drug discovery. 👉 RSVP here: luma.com/9pyf9k90 #ICLR #ICLR26

Recursion at #AACR: Transcriptional Atlas of Patient Tumors for Preclinical Model Selection On April 20, 9am-12pm, we’re presenting a poster on CellNeighbor – a novel computational framework designed to contextualize cell line expression profiles within the landscape of real-world patient transcriptomic data, ensuring our preclinical decisions are rooted in actual patient biology. 🔹 Highlights include: 🧬 Mapping the Landscape: CellNeighbor integrates bulk RNA-seq across cell line models and massive real-world patient cohorts into a single, harmonized transcriptional embedding space. 🧹 Filtering the Noise: Combining lab cells with patient tumors is notoriously difficult due to Tumor Microenvironment (TME) variations. Building on Celligner's framework, we use contrastive PCA to successfully isolate and remove TME-related gene expression (like immune activity), allowing for true apples-to-apples comparisons. 🚫 Identifying Poor Translators: We developed a novel “homogeneity score” to rank how closely a cell line resembles its tissue of origin. Our analysis revealed, for instance, that some widely used breast cancer cell lines transcriptionally resemble lung or gynecological cancers more than breast cancer. CellNeighbor allows us to filter these out and prioritize the most translatable models. 🎯 Accelerating Biomarker Discovery: By layering in vitro drug sensitivity data directly onto these harmonized patient-cell neighborhoods, we can map responses to real-world patient mutations. By adding layers of real-world clinical covariates to in vitro models, we are validating our drug hypotheses in more clinically relevant contexts. Authors include: Caitlin Simopoulos, Gabrielle Persad, Otto Morris, Carlos Origel Marmolejo, Laura M. Richards, Kelly M. Biette 👉 Learn more: aacr.org/meeting/aacr-annual… #TechBio #AACR26 #DrugDiscovery #Oncology #Recursion #Cancer #AI #ClinicalTrials

Recursion executives will present at two upcoming investor conferences: ▪️ Monday, April 13: the 25th Annual Needham Virtual Healthcare Conference ▪️ Tuesday, May 12: @BankofAmerica Health Care Conference 2026 👉 Check out the webcasts in the events section of the Recursion Investor Relations website at ir.recursion.com

Recursion at #AACR:  AI in Biomarker Discovery and Drug Development On April 18, 12:30pm Teeru Bihani, VP of Translational Strategy at Recursion, will present an educational session with Jorge Reis-Filho, Chief of AI for Science Innovation at @AstraZeneca. The session will be chaired by Jakob Nikolas Kather of the Dresden International Graduate School for Interdisciplinary Life Sciences. Teeru will share how we’re applying AI in practice to improve decision-making across the drug development lifecycle — from early biological insight through clinical strategy. Drawing on real examples from across our portfolio, she’ll highlight how these approaches better align preclinical findings with patient outcomes and ultimately close the translational gap in oncology R&D. 👉 Learn more: abstractsonline.com/pp8/#!/2…

💊 The data differentiator in AI drug discovery. A new article in @GENbio looks at the critical role of data infrastructure in AI drug discovery to address three interconnected challenges: “capturing molecular complexity in machine-readable formats, implementing FAIR (Findable, Accessible, Interoperable, and Reusable) data principles at scale, and preparing datasets through collaboration-centric platforms.” Referencing @xiaofei_lin’s interview with Najat Khan, the story notes that Recursion is focused on delivering clinical value via “superior preclinical execution” and an AI-enabled platform that supports the “Design-Make-Test-Analyze (DMTA) cycle—the fundamental, iterative four-stage workflow in pharmaceutical R&D to progress therapeutic intellectual property into drugs.” High-quality, fit-for-purpose data is critical. “Machine learning models learn from data, and their effectiveness depends entirely on the quality of that input,” the story notes. “Feed them clean, well-structured data, and they can identify subtle SAR patterns that complement human intuition.” 👉 Read more: genengnews.com/topics/artifi…

🧬Solving the scale mismatch in AI drug discovery. TechBio is very good at measuring and simulating biology at the single-cell level, from predicting protein structures, to mapping transcriptomic shifts, to modelling cellular responses. But it’s much more challenging to connect those insights to the full complexity of patients, and design drugs more likely to succeed in the clinic. At the upcoming @SynBioBeta Synthetic Biology Summit, May 4-7 in San Jose, leading experts in pharma and TechBio will tackle the translation gap in modern drug development in a panel called “From Cells to Patients: Solving the Scale Mismatch in Virtual Biology” happening on the mainstage May 5, 11am. 🔹 Speakers include:  ▪️ Dave Hallett - CSO, Recursion ▪️ Marc Tessier-Lavigne - CEO, @Xaira_Thera ▪️ Kim Branson, SVP Global Head, AI & ML, @GSK ▪️ @Ronalfa, Cofounder & CEO, @NOETIK_ai 🔹 They’ll address:  ▪️ How to connect single-cell dynamics to organ-level physiology and actual patient outcomes. ▪️ How to leverage spatial and high-dimensional phenotypic data to preserve biological context. ▪️ How to build integrated computational-experimental loops that turn cellular signals into clinically meaningful biomarkers. 👉 Learn more and register at: syntheticbiologysummit.com/

💊 Where AI is delivering in drug discovery today. A recent story by Peter Sullivan in @axios looked at how AI-led drug discovery and design is changing everything from pharma to federal policies. He notes that its being applied to “shorten development times, lower costs and predict chemical properties that humans don't have time to examine.” Recursion CEO and President Najat Khan shared that drug discovery is actively moving from an artisanal “to a much more systematic approach." The story notes that Recursion “reported positive data in December from a trial of its drug candidate to treat a rare genetic condition that can lead to colon cancer” – the first clinical validation of our AI platform. And it’s only the beginning, as the @US_FDA adjusts its guidelines to meet the AI moment, and companies like Recursion continue to integrate new data layers and uncover new biology using AI and machine learning. As Najat said: "There's going to be some skeptics, but they will come around once they see data.” 👉 Read more: axios.com/newsletters/axios-…

Expanding our ClinTech platform with real-world data and evidence. We’re announcing an expanded partnership with @Citeline to further integrate real-world data and evidence capabilities into our AI-enabled ClinTech platform within the Recursion OS. This integration will enable more precise trial design, improved site selection, and faster, more informed development decisions. Citeline’s data and evidence capabilities are already supporting our pipeline, including the contextualization of single-arm data from our REC-4881 Phase 1b/2 study in FAP. More broadly, we’re seeing investment in our ClinTech platform yield results across our portfolio, including 30–60% improvements in enrollment. This expanded partnership further accelerates our AI-informed clinical development process. Together, we’re building a more predictive, connected, and patient-centered approach to accelerate the path from pipeline to patient. 👉 Read the full announcement here: citeline.com/en/resources/re…